Menu
Search
|

Menu

Close
X

PTC Therapeutics Inc PTCT.OQ (NASDAQ Stock Exchange Global Select Market)

39.48 USD
-0.00 (-0.00%)
As of Oct 12
chart
Previous Close 39.48
Open 39.33
Volume 301,866
3m Avg Volume 377,638
Today’s High 40.04
Today’s Low 38.91
52 Week High 52.95
52 Week Low 14.88
Shares Outstanding (mil) 41.39
Market Capitalization (mil) 812.47
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.22 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY18
125
FY17
194
FY16
83
FY15
37
EPS (USD)
FY18
-0.669
FY17
-2.074
FY16
-4.176
FY15
-5.065
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.75
Price to Sales (TTM)
vs sector
6.62
5.74
Price to Book (MRQ)
vs sector
4.78
5.00
Price to Cash Flow (TTM)
vs sector
--
23.28
Total Debt to Equity (MRQ)
vs sector
83.22
16.89
LT Debt to Equity (MRQ)
vs sector
83.22
12.55
Return on Investment (TTM)
vs sector
-37.56
14.60
Return on Equity (TTM)
vs sector
-64.70
16.33

EXECUTIVE LEADERSHIP

Michael Schmertzler
Independent Chairman of the Board, Since 2004
Salary: --
Bonus: --
Stuart Peltz
Chief Executive Officer, Director, Since 1998
Salary: $636,540.00
Bonus: $302,357.00
Christine Utter
Principal Financial Officer and Treasurer, Since 2017
Salary: $317,596.00
Bonus: $142,067.00
Marcio Souza
Chief Operating Officer, Since 2017
Salary: $401,396.00
Bonus: $165,300.00
Neil Almstead
Executive Vice President, Research, Pharmaceutical Operations & Technology, Since 2015
Salary: $434,969.00
Bonus: $165,288.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

100 Corporate Ct
SOUTH PLAINFIELD   NJ   07080-2400

Phone: +1908.2227000

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.

SPONSORED STORIES